Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Opening Session Panel Discussion

Deborah Collyar: What's In It for Patients?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement

Apr

15

Today In Oncology

LuPSMA-617 and Pembrolizumab in mCRPC

Is Standard of Care Optimal for the Individual Patient?

ASH-ISTH Create Guidelines for Pediatric VTE Prophylaxis

Asbestos-Free Talc Not Associated With Increased Risk for Respiratory Cancers

New Molecular-Based Model for Classification and Risk in Chronic Myelomonocytic Leukemia

Advertisement

© 2026 HSP News Service, L.L.C.